Athanor Capital’s Beam Therapeutics BEAM Stock Holding History

Athanor Capital’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,288	Closed	-$350K	–	825
2020 Q4	$350K	Buy	+4,288	New	+$211K	0.01%	544

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Athanor Capital's BEAM Position: Q1 2021 in Review

Athanor Capital sold out of Beam Therapeutics (BEAM) in Q1 2021, closing a stake of 4,288 shares — an estimated $350K sold.

Athanor Capital first reported a position in BEAM in Q4 2020 and held it in 1 quarter. The position peaked at $350K in Q4 2020. 210 funds tracked by Wall St. Rank hold BEAM as of Q1 2021.

Athanor Capital reported no remaining Beam Therapeutics position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 4,288 Beam Therapeutics shares in Q1 2021, an estimated $350K.
Athanor Capital first reported a position in Beam Therapeutics in Q4 2020 and held it in 1 quarter.
Athanor Capital's Beam Therapeutics position peaked at $350K in Q4 2020.
210 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.